| Name | Title | Contact Details |
|---|
ProKidney, a pioneer in the treatment of chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney`s lead product candidate, REACT® (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT® has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting an immediate start to a global registrational program, which launched in the United States on schedule in January 2022. On January 18, 2022, ProKidney announced that it would become a publicly traded company via a business combination with Social Capital Suvretta Holdings Corp. III
Consulting Engineers and Scientists, Inc. is a Malvern, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The new Actavis, Inc. (NYSE:ACT) is a combination of the previously separate Watson Pharmaceuticals, Inc. and Swiss-based Actavis Group. Actavis, Inc. is a specialty pharmaceutical company that develops, manufactures and distributes generic, brand and biosimilar products. The Company has global headquarters in Parsippany, NJ and international headquarters in Zug, Switzerland.
Hospicom is a Cold Spring, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Recombinant Data Corp. is a Newton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.